Related Experiment Video
Updated: Aug 27, 2025
03:40
Acupoint Catgut Embedding Therapy in Traditional Chinese Medicine for Managing Allergic Rhinitis
Published on: December 20, 2024
608
Proton Pump Inhibitors in Allergy: Benefits and Risks
Lacey B Robinson1, Melanie A Ruffner2
1Beth Israel Lahey Health, Lahey Clinic, Burlington, Mass.
The Journal of Allergy and Clinical Immunology. in Practice
|September 26, 2022
Summary
Proton pump inhibitors (PPIs) are common treatments for gastrointestinal issues. Emerging evidence suggests a potential link between PPI use and the development of allergic disorders.
Area of Science:
- Gastroenterology and Allergy/Immunology
Background:
- Proton pump inhibitors (PPIs) are frequently prescribed for gastrointestinal conditions like GERD and eosinophilic esophagitis.
- PPIs are sometimes used by allergists for conditions co-occurring with GERD or when GERD presents as chronic cough.
- Long-term, high-dose PPI therapy can achieve histologic remission in about 40% of eosinophilic esophagitis patients.
Approach:
- This review discusses current recommendations for PPI usage, including de-escalation strategies.
- It examines the side effect profile associated with PPI therapy.
- The review synthesizes evidence on the epidemiologic association between acid-suppressant medication and allergic disorders.
Key Points:
- PPIs are indicated for various gastrointestinal disorders, including GERD and eosinophilic esophagitis.
- Allergists may prescribe PPIs for comorbid conditions or reflux-induced chronic cough.
- Long-term PPI use is a treatment option for eosinophilic esophagitis, with a notable remission rate.
Conclusions:
- Current guidelines for PPI use, de-escalation, and side effects are discussed.
- Evidence suggests a potential epidemiologic link between PPIs and the development of allergic conditions.
- Further research may clarify the relationship between acid-suppressant medication and allergic disorders.
Related Concept Videos
01:13Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors
514
Peptic ulcers, often induced by H. pylori infections or NSAID usage, arise from disruptions in the delicate balance of gastric acid production. Peptic ulcers stem from heightened gastric acid levels due to H. pylori infections or NSAID use. The protective mucus layer diminishes in the presence of these factors, allowing gastric acid to erode the stomach lining and form ulcers.
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
514
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
407
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
407
01:28Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists
559
Histamine H2 receptors, which are intricately located on the basolateral membrane of parietal cells, play a crucial role in modulating gastric acid secretion. When released from enterochromaffin-like cells, histamine engages H2 receptors, initiating the cyclic AMP (cAMP) pathway. In this pathway, adenylyl cyclase converts ATP into cAMP, elevating intracellular cAMP levels. The activation of protein kinase A follows, stimulating the proton pump. This stimulation prompts the secretion of hydrogen...
559
01:26Peptic Ulcer Disease IV: Management
137
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
137
01:19Antiasthma Drugs: Leukotriene Modifiers
417
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
417
01:24Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors
507
Peptic ulcer disease, commonly called PUD, represents a multifaceted condition characterized by disruptions in the lining of the gastrointestinal (GI) tract. Central to the protection of the gastrointestinal lining is the mucosal-bicarbonate barrier. This physiological defense mechanism is a formidable shield against the corrosive effects of gastric acid and pepsin secretion in the stomach. Its role is pivotal in maintaining the structural integrity of the stomach's inner lining.
507